A Compliant Abbott Channels More Funds Into Core Diagnostics R&D
This article was originally published in The Gray Sheet
Executive Summary
Now that Abbott is in the final throes of a 1999 FDA consent degree, the company's core chemistry and immunoassay diagnostics unit says it has freed up some more funds for research and development